

Medullary Thyroid Cancer Registry

To further assess risk, Amylin Pharmaceuticals, Inc. will be systematically monitoring cases of medullary thyroid cancer (MTC) via a MTC case series registry to identify any increase in the incidence of MTC related to the introduction of BYDUREON™ (exenatide extended-release for injectable suspension) into the US marketplace. All cases of medullary thyroid cancer, regardless of potential association with any drug treatment, should be reported to your state cancer registry.

To find out information on how to report a case to your state cancer registry, go to <http://www.naaccr.org/Membership/MembershipDirectory.aspx>.